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Abstract: Cannabinoids participate in the modulation of numerous functions in the human organism, increasing
the sense of hunger, affecting carbohydrate and lipid metabolism, and controlling systemic energy balance mech-
anisms. Moreover, they influence the endocrine system functions, acting via two types of receptors, CB1 and
CB2. The aim of the present study was to examine the number, distribution and activity of ghrelin and soma-
tostatin producing endocrine cells in the pancreas of rats after a single administration of selective CP 55,940
agonist of CB1 receptor. The study was performed on 20 rats. Neuroendocrine cells were identified by immuno-
histochemical reactions, involving specific antibodies against ghrelin and somatostatin. The distribution and
number of ghrelin- and somatostatin-immunoreactive cells were separately studied in five pancreas islets of
each section. A performed analysis showed a decreased number of somatostatin-immunoreactive cells and
a weak immunoreactivity of ghrelin and somatostatin containing neuroendocrine cells in the pancreatic islets of
experimental rats, compared to control animals. The obtained results suggest that a single administration of
a selective CP 55,940 agonist of CB1 receptor influences the immunoreactivity of endocrine cells with ghrelin and
somatostatin expression in the pancreas islets. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 1, 111–117)
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Introduction
Cannabinoids may be divided into exogenous com-
pounds, the most common of which are D8-tetrahy-
drocannabinol (D8-THC) and the more active D9-tet-
rahydrocannabinol (D9-THC), and endocannab-
inoids, among which anandamide and 2-arachidony-
loglycerol are the best recognized and most widely
known compounds [1].
Cannabinoids act mainly via the two types of re-
ceptors: CB1 and CB2. CB1 receptor is localized
mainly in the central nervous system, including the
hypothalamus, the limbic system, brain stem nuclei,
the pituitary gland, as well as in the spleen, lymph
nodes, the liver, the heart, the lungs and the pancre-
as. The peripheral CB2 receptor is associated with
cells of the immune system, the spleen, the lymph
nodes and bone marrow, as well as with adipocytes,
keratinocytes and pancreatic islet cells [2].
The consequences of cannabinoid receptor activa-
tion include a suppressed release of neurotransmitters,
an increased activity of adenylocyclase, MAP kinase
(mitogen-activated protein kinase), calcium channel
blocking and potassium channel activation [3].
Cannabinoids take part in the control of systemic
energy balance and stimulate food intake [4]. Their
central and peripheral actions stimulate appetite,
cause changes in the metabolism of carbohydrates and
lipid compounds and in the accumulation of fats [5].
The orexigenic activity of endocannabinoids is, first
of all, associated with a large number of CB1 recep-
tors in the hypothalamus, mainly in the arched nucle-
us, the ventral medial nucleus and the paraventricu-
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lar nucleus. These are the areas where appetite in-
creasing or decreasing factors coexist [6].
Ghrelin presents with endocannabinoid-like activ-
ity, regarding the control of energy balance and food
intake [7].
Ghrelin is a 28-amino acid peptide, primarily iso-
lated in specific cells of rat gastric mucosa, but its pro-
duction has also been detected in the small intestine,
the pancreas, testis, placenta and, probably, also in
the hypothalamus [8].
Since ghrelin was first identified in 1999, it has been
the subject of numerous studies, concerning, among
others, the neuroendocrine mechanisms of food intake
control [9]. Through its complex interactions with neu-
rotransmitters in the hypothalamus, ghrelin appears
to be a potent regulator of feeding behavior and ener-
gy homeostasis. Experimental studies have proven that
ghrelin stimulates food intake and induces weight gain.
Endocrine X/A cells of stomach fundus mucosa are
the main area of ghrelin production [8]. However, in
the fetal period, ghrelin-positive cells in the pancreatic
islets precede their occurrence in the stomach [10]. At
the end of the fetal period, and in human newborns,
they constitute approximately 10% of all the cells in the
islets of Langerhans, but in mature subjects, cells with
ghrelin expression are very scarce (approximately 1%)
[11]. Thus, in the course of system development, ghre-
lin expression in the pancreas gradually decreases, while
the peptide’s expression in the stomach increases [12].
Ghrelin exerts a broad physiological effect via in-
duced secretion of the growth hormone, prolactin and
ACTH, stimulation of gastric motor activity and gas-
tric juice secretion; moreover, it supports insulin resis-
tance and gluconeogenesis [13]. Ghrelin initiates the
sense of hunger and increases appetite, resulting in
body mass increase, mainly by fat tissue deposition [9].
Somatostatin (ST) is synthesized from a 92-amino acid
preprosomatostatin precursor molecule that is processed
to generate somatostatin-14 and somatostatin-28. Soma-
tostatin-14 is predominantly found in the stomach, the
pancreatic islets, and enteric neurons, whereas somatosta-
tin-28 is the major form in the small intestine. Somatosta-
tin, which is present in gastric oxyntic and pyloric D cells,
inhibits acid secretion by acting directly on parietal cells
and, indirectly, by inhibiting histamine secretion from en-
terochromaffin-like cells and gastrin secretion from
G cells. The wide distribution of somatostatin and of its
receptor subtype family in the human body explains the
great variety of physiological mechanisms in which this
peptide hormone is involved [14]. Somatostatin, an in-
hibitory neuropeptide, occurs in regions of the central
nervous system, the peripheral nerves and the gastrointes-
tinal tract, being involved in motor, cognitive, autonom-
ic, and neuroendocrine processes [15].
Somatostatin release can be stimulated by a vari-
ety of hormones, neuropeptides, neurotransmitters,
cytokines, growth factors and nutrients. For example,
the growth hormone-releasing hormone (GHRH),
neurotensin and the corticotropin-releasing hormone
(CRH) are all potent stimulators of ST secretion in
several tissues. On the other hand, the neurotrans-
mitters: g aminobutyric acid (GABA), and opiates
generally, inhibit ST secretion.
In the pancreas, somatostatin is produced by del-
ta cells of the pancreatic islets, where it exerts local
effects, inhibiting insulin and glucagon secretion [16].
The effects of somatostatin and ghrelin are antag-
onistic to growth hormone secretion; however, there
are several control mechanisms where these effects
are convergent [17].
No data was found in the available literature re-
garding the behavior of endocrine cells which pro-
duce ghrelin and somatostatin in the pancreatic islets
as a result of cannabinoid effects. Besides, much at-
tention has recently been paid in pre-clinical and clin-
ical studies to the synthetic ligands of cannabinoid
CB1 and CB2 receptors.
Taking the above-mentioned issues into account,
as well as considering the occurrence of cannabinoid
receptors in the pancreas, we decided to study the
effects exerted by the selective agonist CP 55,940 of
CB1 receptor on ghrelin- and somatostatin-produc-
ing cells in rat pancreatic islets.
Material and methods
Experimental model. The study was performed on 20 young
male Wistar rats, each weighing 160–190 g. The rats were
housed individually in lighted and ventilated conditions at
room temperature and maintained day and night rhythm.
The animals had free access to standard granulated chow,
and drinking water was available ad libitum. Study assump-
tions, its aim and schedule and the mode of animal treat-
ment were approved by the Local Ethics Committee for
Animals, Medical University of Bialystok (26/2001).
The rats were divided into two groups: a control group
of five animals, injected with vehicle solution, and an ex-
perimental group of 15 animals, injected once with an in-
traperitoneal dose of 0.25 mg/kg CP 55,940, dissolved in dim-
ethyl sulphoxide (DMSO).
Histology. The method of experimental material collection and fix-
ation. Four hours after the injection, the animals were decapi-
tated under pentobarbital anesthesia (50 mg/kg b.w.). The
pancreas was immediately removed, fixed in Bouin’s fluid, and
embedded in paraffin in a routine way. The specimens were
cut into 4 μm slices (Leica 2025 Autocut) and stained by he-
matoxylin-eosin (H + E) for general histological examination.
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Identification of Diffuse Neuroendocrine System (DNES)
cells by immunohistochemical methods. An immunohis-
tochemical reaction was performed on paraffin pancreas
sections of the studied animals to identify ghrelin and so-
matostatin in neuroendocrine cells. The specific antibodies
against ghrelin and ST were applied in the study (Table 1).
The paraffin blocks were cut into 4-μm sections and mount-
ed onto Superfrost Plus slides (Menzel, Braunschweig,
Germany) and dried overnight at 37°C, followed by 1 hour
at 60°C.
A NovoLink Polymer Detection System (No: RE7150-K)
by Leica Microsystems was used in the immunohistochem-
ical study. Immunostaining was performed using the pro-
tocol as described below [18]. The sections were deparaf-
finized in xylene and rehydrated in decreasing concentra-
tions of pure ethanol. Then the sections were subjected to
pre-treatment for antigen retrieval in a pressure chamber,
heating for 1 min at 21 psi at 125°C and using Buffer Re-
trieval (Dako, Glostrup, Denmark) (Table 1). After being
cooled down to room temperature, the sections were incu-
bated with Peroxidase Blocking Reagent for 5 minutes to
block endogenous peroxidase activity. All the primary anti-
bodies were diluted, using the same antibody diluent (S0809,
Dako, Glostrup, Denmark) (Table 1).
The sections were incubated overnight at 4°C in a hu-
midified chamber with the diluted antibodies (see Table 1),
followed by incubation with NovoLink Polymer (conju-
gated to horseradish peroxidase-labeled polymer). Bound
antibodies were visualized by 1-min incubation with liq-
uid 3,3’-diaminobenzidine substrate chromogen. The sec-
tions were finally counterstained in hematoxylin QS (Vec-
tor, H – 3404), mounted, and evaluated under a light
microscope. Appropriate washing with Wash Buffer S
3006 (Dako, Glostrup, Denmark) was performed between
each step.
Control reactions were simultaneously performed. In the
negative control, the specific antibodies were replaced by
normal rabbit serum (Vector Laboratories, Burlingame, CA,
USA) at respective dilutions. All the performed control re-
actions gave negative results.
A positive control was done for specific tissue, recom-
mended by the producer; for rat ghrelin — pylorus, for so-
matostatin — D cells of human pancreatic islets.
Quantitative analysis. The results of immunoreactive en-
docrine (IRE) cells with ghrelin and somatostatin (D) ex-
pression were sought, and their topography was observed.
The dark brown positive cells on a section were separately
counted in five pancreas islets of each section at a magnifi-
cation of 200 (20 × the lens and 10 × the eyepiece). Five
sections of each rat (five control and 15 experimental) were
analyzed. The average number of IRE cells from five pan-
creatic islets, randomly selected in each specimen, was the
IRE cell number in each animal. The cell count was ex-
pressed as the mean number of ghrelin-immunopositive and
somatostatin-positive cells per section. The numbers of cells
were calculated by a computer.
Statistical analysis. All the presented data were statistical-
ly analyzed by means of the Statistica Version 7.0 software
computer package. Descriptive statistics (mean, SD) was
calculated for ghrelin-positive and somatostatin-positive
cells numbers. The obtained results were expressed as means ±
± SD. The corresponding mean values were computed au-
tomatically; significant differences were determined by Stu-
dent’s t-test; p < 0.05 was taken as the level of significance.
Results
Routine histological studies showed no histopatho-
logical changes in pancreas morphology.
Location, morphology and immunohistochemical
characteristics of neuroendocrine (NE) cells in the
pancreases of control and study rats
The immunohistochemical studies revealed a positive
reaction in the cytoplasm of endocrine pancreatic cells
in all the examined animals, indicating that the anti-
body reacted against the antigens in ghrelin- and so-
matostatin-containing cells, recognizing their location
in the pancreatic islets.
Ghrelin-immunopositive cells
In the pancreases of both the control and the ex-
perimental rats, only single ghrelin-immunoreac-
Table 1. Used antibodies
No Antibodies Host Dilution Time Antigen Positive
and temperature retrevial control
primary incubation (pH)
1. GHRELIN Rat Rabbit 1:10,000 24 h Target retrieval Rat gastric glands
H 031-31 +4°C solution
PHOENIX Pharmaceutical INC  pH = 9.0
2. SOMATOSTATIN Rabbit 1:20,000 24 h Target retrieval Human pancreatic islets
H 060-03 +4°C solution
PHOENIX Pharmaceutical INC pH = 9.0
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tive cells were observed, being peripherally located
in the islets of Langerhans. They were predominant-
ly large and distinguished by their round or oval shape.
Ghrelin staining intensity was high in the pancre-
ases of the control animals, and distinctly lower in
those of the experimental group (Figures 1A, B).
Quantitative measurements indicated a compara-
ble number of cells with positive reaction to the anti-
bodies against ghrelin in the control and study rats
(0.7 cells per section).
Somatostatin-immunopositive cells
The distribution density of ST-immunoreactive cells
was significantly higher in the pancreases of the stud-
ied animals vs. the distribution density of ghrelin-pos-
itive cells. Somatostatin-positive cells were mostly
distributed in the peripheral region of Langerhans
islets and only a few of them were observed at pan-
creas islet centers. Single ST-immunopositive cells
were scattered in the exocrine part of the pancreas
(Figure 2). D cells were distinctive by their shape di-
versification, from fusiform to round, pyramidal or
flask shapes, with frequently observed multiform cy-
toplasmic process, extending onto other nearby cells.
This was seen especially in the pancreases of the con-
trol animals (Figures 3A, B). The majority of D-cells
in the control rat pancreases showed a moderate im-
munostaining for somatostatin, although the staining
intensity for ST in the same cells was high or weak
(Figure 4A). In microscopic images of study group
rat pancreases, weaker somatostatin expression was
seen vs. the control animals (Figure 4B).
A computer analysis of ST-immunoreactive cells
demonstrated a statistically significant decrease in
the number of D cells in rat pancreases after a sin-
gle administration of selective agonist of CB1 — CP
55,940 receptor (7.94 ± 3.56 cells per section) vs.
the control animals (12.77 ± 4.48 cells per section)
(Table 2).
Figure 2. Single ST-immunopositive cell in the exocrine part
of the pancreas of experimental rat. Magnification × 400
Figure 1. Individual ghrelin immunoreactive cells in the
pancreatic islets of control (A) and experimental rats (B).
Magnification × 400
Table 2. Number of ghrelin- and somatostatin-immunore-
active NE cells in the pancreas of control and experimental
rats (mean ± SD)
Control rats Studied rats p
Cells per Cells per
section ± SD section ± SD
Ghrelin 0.7 0.7 p < 0.05
Somatostatin 12.77 ± 4.48 7.94 ± 3.56 p < 0.05
A
B
115CP 55,940 — agonist cannabinoid receptors in rat pancreas
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0016
www.fhc.viamedica.pl
Figures 3 A and B. Variety of shapes and cytoplasmic process of somatostatin-immunopositive cells in the pancreases of
control rats. Magnification × 200
Figures 4 A and B. Somatostatin immunopositive reaction in the cytoplasm of pancreas D cells; (A) control and (B)
experimental rats. Magnification × 200
A B
A B
Discussion
The type of ghrelin-producing cells in pancreatic islets
has long been controversial. Date et al. [19] postulated
co-localization of ghrelin in the glucagon-producing
cells in human and rat pancreas. The studies of Volan-
te et al. [20] have proven that, in man, ghrelin is pro-
duced in beta cells of the pancreatic islets. It follows
from the latest reports that this hormone is produced
by epsilon cells, which constitute a separate cellular
population of pancreatic islets [21], originating from
the same precursor cells as do beta cells [22].
The distribution of cannabinoid receptors within
the area of the islets of Langerhans in man and rat is
fairly specific. In humans, CB1 receptor occurs in al-
pha and beta cells, as it does in mice and rats, while
CB2 receptor in man is localized in delta cells and in
animals in beta cells [22].
Cannabinoids are substances which modulate
a number of functions in the human body. Their ef-
fects are sedative and analgesic, improving the mem-
ory and learning processes. They play a huge role in
energy balance control and food intake stimulation
[23] and participate in the regulation of endocrine
cell activity [3].
The reduced number of somatostatin-producing
cells, as observed in the performed studies, with their
decreased immunoreactivity and weaker immunore-
activity of ghrelin-like cells, indicates a clear effect of
a single dose of CP 55,940 agonist of CB1 receptor
on the studied endocrine cells of rat pancreatic islets.
No data was found in the available literature re-
garding the behavior of ghrelin- and somatostatin-
producing cells under the influence of cannabinoids;
therefore, an analysis of the results, obtained in the
reported study, is difficult.
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Ghrelin, secreted by cells of the pancreatic islets,
exerts a local effect, and also affects the target cells
localized in other organs.
A correlation has been demonstrated between
ghrelin concentration and the effects of cannabinoids
[24] which is associated with the mechanisms which
are at the base of appetite control. A key role is played
in this process by the hypothalamic AMP-protein ki-
nase (AMPK), which is a specific factor of energy
balance control at the cellular level by suppressing
anabolic and stimulating catabolic processes [25]. The
increased activity of AMPK results from the orexi-
genic action of ghrelin and cannabinoids, where the
stimulatory effect of ghrelin on AMPK takes place
exclusively in the presence of CB1 in the hypothala-
mus. The presence of CB1 receptor is necessary to
induce an enhanced orexigenic effect of cannabinoids.
An experiment on mice with CB1 knockout has dem-
onstrated a total blocking of ghrelin’s orexigenic ef-
fect, which could be an indication of the combined
action of endocannabinoids and ghrelin [26].
A stimulation of CB1 receptor by cannabinoids,
both with elevated and reduced glucose levels, caus-
es an increased secretion of insulin [2]. Ghrelin plays
a vital role in this process, causing an increased con-
centration of calcium ions in beta cells, which, in con-
sequence, results in a higher insulin secretion rate [19].
However, the opinions of researchers regarding the
effects of ghrelin on insulin secretion are somewhat
divergent. Broglio et al. [27] found reduced insulin
levels in the blood of patients after ghrelin adminis-
tration, while Kamergai et al. [28], in studies on rats,
did not see significant changes in the concentration
of plasma insulin. The above data indicates that gh-
relin controls the secretory function of pancreatic is-
lets via endocrine and/or paracrine mechanisms.
The system of endocannabinoids, locally produced
within the area of pancreatic islets, is unquestionably
highly significant in the control of endocrine cell me-
tabolism of the pancreas. Evidence for the above as-
sumption may be sought in the presence of certain
enzymes, including monoacylglycerol lipase (MAGL),
fatty acid amide hydrolase (FAAH), and diacylglyc-
erol lipase (DAGL), associated with the synthesis or
degradation of cannabinoids in the endocrine part of
the pancreas [22].
It may be supposed that the reduced immunore-
activity of ghrelin-positive cells, as observed in our
studies, could be related to a lower production of
ghrelin, result of applied cannabinoid. A study by Cani
et al. [29] confirms the above observations, having
demonstrated that an administration of a single dose
of SR141716, a cannabinoid receptor antagonist, re-
duces ghrelin levels in plasma.
The pancreas undergoes complex regulatory pro-
cesses, in which nervous and hormonal factors play a
significant role, as well as local regulatory factors,
which are decisive for the proper functioning of the
organ, including amylin secreted by beta cells [30],
platelet-derived growth factor (PDGF), and tumor
necrosis factor (TNF) [31]. It may be assumed that
these compounds can mediate ghrelin and somatosta-
tin release.
The reduced numbers of D cells, as observed in
the reported study, may have been caused by an en-
hanced secretion or disturbed synthesis of somatosta-
tin under the influence of CP 55,940 agonist of CB1
receptor. Rettori et al. [32] found in their study a re-
duced secretion of the growth hormone, both from the
normal pituitary gland of man, as well as from cells of
somatotropic adenomas, as an effect of cannabinoid
activity, which the authors associated with stimulation
of somatostatin release in the hypothalamus.
It follows from the study by Bermúdez-Silva et al.
[22] that endocannabinoids, produced in pancreatic
islets and being the agonists of CB1 receptor, induce
an increased secretion of glucagon and somatostatin.
Delta cells in rats do not demonstrate CB1 expression;
therefore, according to the authors, the increased se-
cretion of somatostatin is a negative feed-back mecha-
nism mediated by glucagon-dependent somatostatin
release. In turn, a stimulation of CB2 receptor in iso-
lated human pancreases reduces insulin secretion, most
probably without somatostatin mediation.
Ours was the first study undertaken to describe
changes in the activity of ghrelin and somatostatin
producing endocrine cells in the pancreas to a single
administration of selective CP 55,940 agonist of CB1
receptor.
From the present study, we conclude that cannab-
inoids change immunoreactivity of the ghrelin and
somatostatin producing cells in pancreatic islets.
However, the modulation of the pancreatic endocrine
part, following the application of agonists for cannab-
inoid receptors, requires further investigation.
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